Skip to Content

Possia

Active Substance: ticagrelor
Common Name: ticagrelor
ATC Code: B01AC24
Marketing Authorisation Holder: AstraZeneca AB
Active Substance: ticagrelor
Status: Withdrawn
Authorisation Date: 2010-12-03
Therapeutic Area: Peripheral Vascular Diseases Acute Coronary Syndrome
Pharmacotherapeutic Group: Antithrombotic agents

Therapeutic Indication

Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

The marketing authorisation for Possia has been withdrawn at the request of the marketing-authorisation holder. 

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide